Clarification to “Expert consensus on treatment for stage III non-small cell lung cancer”

Abstract

Wu YL, Lu S, Zhou QH, Zhang L, Cheng Y, Wang J, Wang BH, Hu CP, Lin LZ, Zhong WZ, Song Y, Yang N, Dong XR, Zhao J, Yang HH, Guo H, Yan XL, Liu HX, Ma R, Lin J, Liu SY, Chen C, Wang LF, Zhou CZ, Zhou M, Wu F, Yang XN, Du YY, Yao Y, Shao Y, Hong SD, Cui JW, Quan XP, Chen RR, Wu JY, Zhang JT, Zhou JY, Wang BC, Cheng C, Wang HJ, Liu JJ, Wu L, Huang Y, Kuang YK, Zhang YC, Hu J, Yang JJ, Feng WN, Su WM, Fan Y, Yang F, Chen M, Tang KJ, Tang Y, Shen P, Liu AW, Zhang HB, Liang WH, Zhou Q, Ma ZY, Cai XY, Liu H, Chen LF, Chuai SK, Chuai JZ, Zheng YF, You CX, Zhu XX, Li L, Zhang TM, Tu HY, Lin WR, Zhang XC, Zhou PH, Ke ZF, Liang HY. Expert consensus on treatment for stage III non-small cell lung cancer. Med. Adv. 2023;1:3–13.

We want to clarify that this article was originally published in Chinese in the Journal of Evidence-based Medicine (doi: 10.12019/j.issn.1671-5144.2022.03.001). This is an English translation of the original article and permission was granted by the Journal of Evidence-based Medicine.

The online version of the original article can be found at http://www.jebm.cn/CN/10.12019/j.issn.1671-5144.2022.03.001.